Stryker Corporation $SYK Stock Holdings Lessened by Park Avenue Securities LLC

Park Avenue Securities LLC lowered its position in shares of Stryker Corporation (NYSE:SYK) by 30.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,198 shares of the medical technology company’s stock after selling 5,385 shares during the quarter. Park Avenue Securities LLC’s holdings in Stryker were worth $3,359,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SYK. State Street Corp boosted its holdings in Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after purchasing an additional 183,400 shares during the period. Wellington Management Group LLP raised its position in shares of Stryker by 0.6% in the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after buying an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new position in Stryker during the 2nd quarter worth $1,404,284,000. Royal Bank of Canada increased its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after acquiring an additional 481,175 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on SYK. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Wells Fargo & Company dropped their price target on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Citigroup reiterated a “market outperform” rating on shares of Stryker in a research note on Friday. Finally, Citizens Jmp decreased their target price on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a report on Friday. Sixteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $355.84.

Stryker Price Performance

Shares of SYK stock opened at $291.56 on Friday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33. The company has a market cap of $111.83 billion, a P/E ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78. The business has a fifty day simple moving average of $292.83 and a 200 day simple moving average of $324.51.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.83%. The business had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. During the same period last year, the business earned $3.19 earnings per share. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, sell-side analysts forecast that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s payout ratio is 36.48%.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insider Activity at Stryker

In other Stryker news, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.